|
⚲
|
| Keyboard |
| MPM Asset Management LLC
✚
|
|
|---|---|
| CRD # | 148467 |
| SEC # | 801-106989 |
| CIK # | 0001496086, 0001263048 |
| AUM | 3,558.1 M (2026-04-28) |
| Employees | 50 (54% Investors, 0% Brokers) |
| Phone | 617-425-9200 |
| Address | 399 Boylston Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Entrada Therapeutics Inc | 25.4 | ||
| Dyne Therapeutics Inc | 8.6 | ||
| Werewolf Therapeutics Inc | 8.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | MPM Bioimpact Innovations Equities Master LP | [2025-03-31] | 131.1 M | 253.9 M |
| Filed 2025-06-27 (D/A) · Exemption 3(c)(7), 506(b), 3(c) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | New Technologies and Virology Fund LP | 2025-03-31 | 140.2 M | |
| VC | MPM BioVentures 2022 LP | [2023-03-30] | 351.0 M | 350.7 M |
| Filed 2023-06-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,050,000 · Revenue Decline to Disclose | ||||
| Other | Oncology Impact Fund 2 LP | [2020-11-17] | 326.8 M | 1,002.8 M |
| Filed 2021-11-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $11,919,100 · Revenue Decline to Disclose | ||||
| HF | Bioimpact Equities Master Fund LP | [2020-03-31] | 2.6 M | 90.9 M |
| Filed 2026-03-10 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | MPM Asset Management Investors 2002 Bviii LLC | 2018-03-30 | 0.0 M | |
| VC | MPM Asset Management Investors 2003 Bviii LLC | 2018-03-30 | 1.4 M | |
| VC | MPM Asset Management Investors 2005 Bviii LLC | 2018-03-30 | 0.2 M | |
| VC | MPM Asset Management Investors BV2014 LLC | 2018-03-30 | 4.0 M | |
| VC | MPM Asset Management Investors BV2018 LLC | [2018-03-30] | 7.5 M | 10.5 M |
| Filed 2018-11-09 (D) · Exemption 506(b), 3(c)(1) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 23 | 3.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 23 | 3.6 |
| By Discretionary | ||
| Discretionary | 23 | 3.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 23 | 3.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.0 | |
| United States Persons | 1.6 | |
| Total | 23 | 3.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Amber Ramsey | Director | 72 | 30 | |
| Nicole Ramroop | Director | 43 | 19 | |
| Alan Kelly | Director | 39 | 17 | |
| Bridget Kidner | Director | 7 | 4 | |
| Howard Rubin | Director, Executive Officer | 11 | 3 | |
| Bronson Crouch | Director | 6 | 3 | |
| Todd Foley | Director, Executive Officer | 42 | 2 | |
| Luke Evnin | Director, Executive Officer, Promoter | 33 | 2 | |
| James Scopa | Director, Promoter | 28 | 2 | |
| Ansbert Gadicke | Director, Executive Officer, Promoter | 27 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001263048] | |
| 3 | [0001263048] | |
| 4 | [0001263048] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 1,112,777 | $18.00 | 20,029,986 |
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 6,000,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 5,914,197 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,577,119 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 1,314,262 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 22,500,000 | $0.00 | |
|
Aktis Oncology Inc AKTS
Series Seed Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 5,000,000 | $0.00 | |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-04 | Sell | 83,230 | $0.97 | 80,733 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-03 | Sell | 57,225 | $0.87 | 49,786 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-02 | Sell | 59,277 | $0.89 | 52,757 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-12-01 | Sell | 60,917 | $0.94 | 57,262 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-28 | Sell | 20,277 | $0.99 | 20,074 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-26 | Sell | 60,733 | $0.98 | 59,518 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-25 | Sell | 42,533 | $0.92 | 39,130 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-24 | Sell | 88,802 | $0.98 | 87,026 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-21 | Sell | 64,331 | $0.83 | 53,395 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-20 | Sell | 41,152 | $0.89 | 36,625 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-19 | Sell | 66,324 | $0.94 | 62,345 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-18 | Sell | 52,627 | $0.93 | 48,943 |
|
Werewolf Therapeutics Inc HOWL
Common Stock
|
2025-11-17 | Sell | 57,061 | $0.95 | 54,208 |
| showing 20 of 95 most recent transactions | |||||
| Related Firms | State | AUM |
|---|---|---|
|
MPM Asset Management LLC
✚
|
MA | 3,558.1 M |
|
MPM Oncology Impact Management LP
✚
|
MA |
| Comparable Firms | State | AUM |
|---|---|---|
|
Anchorage Capital Group LLC
✚
|
NY | 3,707.6 M |
|
Resource Capital Investment Corporation
✚
|
CA | 3,706.7 M |
|
Boussard & Gavaudan Investment Management LLP
✚
|
3,679.1 M | |
|
Soleus Capital Management LP
✚
|
CT | 3,663.3 M |
|
Victory Park Capital Advisors LLC
✚
|
IL | 3,647.8 M |
|
First Sentier Investors Australia Infrastructure Managers PTY
✚
|
3,638.1 M | |
|
Axar Capital Management LP
✚
|
NY | 3,598.9 M |
|
Sycamore Tree Capital Partners LP
✚
|
TX | 3,539.6 M |
|
Deer Park Road Management Company LP
✚
|
CO | 3,515.8 M |
|
Hill Path Capital LP
✚
|
NY | 3,408.2 M |